BioCryst Pharmaceuticals (BCRX) vs Hemab Therapeutics (COAG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | COAG |
|---|---|---|
| Share price | $7.22 | $39.29 |
| Market cap | $1.86B | $1.84B |
| 1-day change | -1.37% | -1.43% |
| YTD return | -7.44% | — |
| 1-year return | +3.59% | — |
| 5-year return | -42.15% | — |
| Forward P/E | 8.44 | — |
| EPS (TTM) | $-1.28 | $-3.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | — |
| Revenue growth (YoY) | +94.10% | — |
| Net income (latest FY) | $263.86M | — |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | — |
| Net margin | 30.16% | — |
| 52-week high | $11.22 | $55.42 |
| 52-week low | $6.23 | $23.00 |
| Distance from 52-week high | -35.65% | -29.11% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +183.24% | +60.35% |
| Average volume | 4.97M | 495.96K |
| Shares outstanding | 257.30M | 46.73M |
| Employees | 435 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
BCRX vs COAG FAQ
Which is bigger, BioCryst Pharmaceuticals or Hemab Therapeutics?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.84B for Hemab Therapeutics (COAG).
Are BioCryst Pharmaceuticals and Hemab Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.